Clinical trial
Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast…
NCT00006459 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00006459 |
|---|---|
| Title | Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer |
| Official title | Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, paclitaxel |
| Start date | Jul 1, 2000 |
| Completion | Oct 1, 2005 |
| First posted | Feb 12, 2004 |
| Last update posted | Jun 7, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: